There May Be Reason For Hope In Simulations Plus' (NASDAQ:SLP) Disappointing Earnings

Yahoo FinanceJan 16 02:09

Simulations Plus Supported Development of Every FDA-Approved Drug in 2024

BusinesswireJan 13 20:50

Simulations Plus First Quarter 2025 Earnings: EPS Misses Expectations

Yahoo FinanceJan 9 19:12

Simulations Plus Analyst Ratings

BenzingaJan 9 04:53 · Ratings

Simulations Plus Down Over 16%, on Track for Lowest Close Since June 2019 -- Data Talk

Dow JonesJan 9 00:10

BTIG Maintains Simulations Plus(SLP.US) With Buy Rating, Maintains Target Price $50

Futu NewsJan 8 21:31 · Ratings